Status:

COMPLETED

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Malignant Melanoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This open-label, non-randomized study will assess the mass balance, metabolism, routes and rates of elimination as well as efficacy and safety of RO5185426 (RG7204; PLEXXIKON; PLX4032) in previously t...

Eligibility Criteria

Inclusion

  • Adult patients, \>/= 18 years of age
  • Histologically confirmed metastatic melanoma, surgically incurable and unresectable Stage IIIc or IV (AJCC)
  • Prior treatment for metastatic melanoma allowed; \>/= 28 days must be elapsed since previous systemic treatment prior to first administration of study drug
  • Positive BRAF V600E mutation result (by Roche CoDx test)
  • ECOG performance status 0-1
  • Adequate hematologic, renal and liver function
  • Body Mass Index (BMI) 18 to 32 kg/m2 inclusive

Exclusion

  • Active CNS lesions
  • History of or known spinal cord compression, or carcinomatous meningitis
  • Anticipated or ongoing administration of any anticancer therapies other than those administered in this study
  • Refractory nausea or vomiting, or other medical conditions that are capable of altering the absorption, metabolism or elimination of the study drug
  • Known clinically significant active infection
  • Known HIV positivity or AIDS-related illness, active HBV, or active HCV
  • Previous malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin, melanoma in situ, and carcinoma in situ of the cervix
  • Clinically significant cardiovascular disease or incident within the 6 months prior to study drug administration
  • Patients who have had at least one dose of study drug (RO5185426 or comparator) in a clinical trial that includes RO5185426

Key Trial Info

Start Date :

July 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT01164891

Start Date

July 1 2010

End Date

December 1 2012

Last Update

April 5 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zurich, Switzerland, 8091